Nutraceuticals as therapeutic interventions in Alzheimer's disease

Maryglen Gargantiel; Erwin Faller; Dileep Kumar; Prashant Tiwari

doi:10.4103/2773-0344.371402

Users Online: 416

REVIEW ARTICLE

Year : 2023 \| Volume : 3 \| Issue : 1 \| Page : 4

Nutraceuticals as therapeutic interventions in Alzheimer's disease Maryglen Gargantiel¹, Erwin Faller², Dileep Kumar³, Prashant Tiwari⁴ ¹ Graduate School, Centro Escolar University, Manila 1005; Pharmacy Department, Fellowship Baptist College, Kabankalan City Negros, Occidental 6111, Philippines ² Graduate School, Centro Escolar University, Manila 1005; Pharmacy Department, San Pedro College, Davao City, Davao del Sur 8000, Philippines ³ Poona College of Pharmacy, Bharti Vidyapeeth University, Maharashtra 411038, India ⁴ Department of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Dayananda Sagar University, Bengaluru 560111, India Correspondence Address: Prashant Tiwari Department of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Dayananda Sagar University, Bengaluru 560111 India Source of Support: None, Conflict of Interest: None DOI: 10.4103/2773-0344.371402

Alzheimer’s disease (AD) is a chronic neurodegenerative disease of the brain. Currently, approximately 55 million people have dementia across the globe and the number of AD patients is estimated by the WHO to reach about 78 million people by 2030 and nearly 139 million by 2050 globally. Amyloid β42, amyloid β oligomers, and tau proteins are the major biomarkers to understand the AD-like pathology. Therapies target β-amyloid (Aβ) for the modification of AD but poor permeability hampers the uses of drugs against AD. Other drugs including NMDA-receptor antagonists, cholinesterase inhibitors and their combination provide only temporary symptomatic relief. Meanwhile nutraceuticals are studied for mitigating the course of dementia. This study reviews therapeutic nutraceuticals which could be effective for treating AD.



[FULL TEXT] [PDF]*